FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308376677> ?p ?o ?g. }

• W4308376677 abstract "<h3>Background</h3> A key question in cancer immunotherapy is the general immune status of the patient’s tumor-microenvironment prior to therapy. The patient‘s underlying tumor immune-contexture may therefore a) guide the therapeutic intervention and b) help to identify potential resistance mechanisms to immune-therapies. The most commonly used classification of the patients’ immune status is based on the CD8 tumor infiltrating lymphocytes status referring to either ‘cold’ or ‘hot’ tumors. <h3>Methods</h3> In this study, we systematically analyzed the CD8 immune-phenotype in 628 patients from 11 Phase 1 clinical trials using immunohistochemistry (IHC) and matched gene expression profiling by RNA-seq. The CD8 immune-phenotype was classified by pathologist assessment into cold (CD8 deserts) and hot (CD8 excluded and inflamed) tumors using CD8+/Ki67+ IHC staining in epithelial and stromal areas of the tumor. <h3>Results</h3> In total, we observed 193 inflamed, 144 excluded, and 291 desert CD8 immune-phenotype from 49 different indications. The main source of tumor biopsy tissues was liver metastasis (N=174), lymph node (N=51) and lung tumor tissue (N=69). Further, we developed a RNA-seq based classification as a surrogate to the IHC based CD8 immune-phenotype classification. Using regularized logistic regression (ElasticNet), we identified a 92 gene signature that accurately predicts the CD8 immune-phenotype in primary and metastatic samples (AUC inflamed = 0.846; AUC Excluded = 0.712; AUC Desert = 0.855). Using our new gene signature, we demonstrate prolonged overall survival (ORR) of patients with CD8 inflamed tumors across The Cancer Genome Atlas (TCGA; Hazard-Ratio 0.89; 95%CI [0.80–0.98]) as well as a better ORR to Checkpoint inhibitors (CPI) in the randomized Phase III OAK study in Non-Small-Cell lung cancer patients (Hazard-Ratio 0,75; 95%CI [0.58–0.97]). <h3>Conclusions</h3> In summary, we identified a novel prognostic and predictive gene signature accurately predicting the IHC based CD8 immune-phenotype in primary and metastatic tumor samples. Survival analysis indicated that the predicted CD8 inflamed phenotype results in prolonged survival in independent patient cohorts. Our analysis provides important insights and a new precision immune phenotyping tool to characterize the impact of the tissue origin with regards to the tumor microenvironment. The new signature enables multiplex analyses and may be used for retrospective, reverse translation approaches as well as for prospective patient enrichment to identify resistance mechanisms to cancer immunotherapy. <h3>Ethics Approval</h3> All patients provided written informed consent. The trials were approved by each center‘s ethics committee or institutional review board and were performed in compliance with the Declaration of Helsinki and International Conference on Harmonisation Guidelines for Good Clinical Practice." @default.
• W4308376677 created "2022-11-11" @default.
• W4308376677 creator A5010481945 @default.
• W4308376677 creator A5017072629 @default.
• W4308376677 creator A5027517899 @default.
• W4308376677 creator A5032577911 @default.
• W4308376677 creator A5033065005 @default.
• W4308376677 creator A5037491071 @default.
• W4308376677 creator A5048249191 @default.
• W4308376677 creator A5050820747 @default.
• W4308376677 creator A5055003000 @default.
• W4308376677 creator A5065108973 @default.
• W4308376677 creator A5084702229 @default.
• W4308376677 date "2022-11-01" @default.
• W4308376677 modified "2023-09-23" @default.
• W4308376677 title "27 Tumor agnostic CD8 immune-phenotype related gene signature defines clinical outcome across early and late phase clinical trials" @default.
• W4308376677 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0027" @default.
• W4308376677 hasPublicationYear "2022" @default.
• W4308376677 type Work @default.
• W4308376677 citedByCount "0" @default.
• W4308376677 crossrefType "proceedings-article" @default.
• W4308376677 hasAuthorship W4308376677A5010481945 @default.
• W4308376677 hasAuthorship W4308376677A5017072629 @default.
• W4308376677 hasAuthorship W4308376677A5027517899 @default.
• W4308376677 hasAuthorship W4308376677A5032577911 @default.
• W4308376677 hasAuthorship W4308376677A5033065005 @default.
• W4308376677 hasAuthorship W4308376677A5037491071 @default.
• W4308376677 hasAuthorship W4308376677A5048249191 @default.
• W4308376677 hasAuthorship W4308376677A5050820747 @default.
• W4308376677 hasAuthorship W4308376677A5055003000 @default.
• W4308376677 hasAuthorship W4308376677A5065108973 @default.
• W4308376677 hasAuthorship W4308376677A5084702229 @default.
• W4308376677 hasBestOaLocation W43083766771 @default.
• W4308376677 hasConcept C104317684 @default.
• W4308376677 hasConcept C142724271 @default.
• W4308376677 hasConcept C150194340 @default.
• W4308376677 hasConcept C167672396 @default.
• W4308376677 hasConcept C203014093 @default.
• W4308376677 hasConcept C2776107976 @default.
• W4308376677 hasConcept C2777701055 @default.
• W4308376677 hasConcept C2778326572 @default.
• W4308376677 hasConcept C2779733811 @default.
• W4308376677 hasConcept C502942594 @default.
• W4308376677 hasConcept C55493867 @default.
• W4308376677 hasConcept C71924100 @default.
• W4308376677 hasConcept C86803240 @default.
• W4308376677 hasConcept C8891405 @default.
• W4308376677 hasConceptScore W4308376677C104317684 @default.
• W4308376677 hasConceptScore W4308376677C142724271 @default.
• W4308376677 hasConceptScore W4308376677C150194340 @default.
• W4308376677 hasConceptScore W4308376677C167672396 @default.
• W4308376677 hasConceptScore W4308376677C203014093 @default.
• W4308376677 hasConceptScore W4308376677C2776107976 @default.
• W4308376677 hasConceptScore W4308376677C2777701055 @default.
• W4308376677 hasConceptScore W4308376677C2778326572 @default.
• W4308376677 hasConceptScore W4308376677C2779733811 @default.
• W4308376677 hasConceptScore W4308376677C502942594 @default.
• W4308376677 hasConceptScore W4308376677C55493867 @default.
• W4308376677 hasConceptScore W4308376677C71924100 @default.
• W4308376677 hasConceptScore W4308376677C86803240 @default.
• W4308376677 hasConceptScore W4308376677C8891405 @default.
• W4308376677 hasLocation W43083766771 @default.
• W4308376677 hasOpenAccess W4308376677 @default.
• W4308376677 hasPrimaryLocation W43083766771 @default.
• W4308376677 hasRelatedWork W2904909612 @default.
• W4308376677 hasRelatedWork W2908970744 @default.
• W4308376677 hasRelatedWork W2912073938 @default.
• W4308376677 hasRelatedWork W2938706471 @default.
• W4308376677 hasRelatedWork W3033156378 @default.
• W4308376677 hasRelatedWork W3134294543 @default.
• W4308376677 hasRelatedWork W4230847397 @default.
• W4308376677 hasRelatedWork W4291378227 @default.
• W4308376677 hasRelatedWork W4317383376 @default.
• W4308376677 hasRelatedWork W4362544227 @default.
• W4308376677 isParatext "false" @default.
• W4308376677 isRetracted "false" @default.
• W4308376677 workType "article" @default.